Le Lézard
Classified in: Covid-19 virus
Subject: ATY

Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 29, 2024 to Discuss Your Rights - KIND


NEW YORK, April 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (NYSE: KIND).

Shareholders who purchased shares of KIND during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/nextdoor-holdings-inc-f-k-a-khosla-ventures-acquisition-co-ii-loss-submission-form/?id=75597&from=4

CLASS PERIOD: July 6, 2021 to November 8, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Nextdoor's financial results prior to the November 2021 merger with Khosla Ventures Acquisition Co. II, had been temporarily inflated by the ephemeral effects of the COVID-19 pandemic, which had pulled forward demand for Nextdoor's platform and cannibalized future advertising revenue growth; (b) rather than being sustained, such growth trends had already begun reversing at the start of the class period; (c) Nextdoor's total addressable market was materially smaller than the 312 million households represented to investors; (d) by the start of the class period, Nextdoor's most important market ? the U.S. market ? was already substantially saturated, impairing the Company's ability to monetize users and increase its average revenue per weekly active user, or U.S. weekly active user metrics; (e) as a result of (a)-(d) above, Nextdoor's revenue guidance for fiscal year 2022 had no reasonable basis in fact and the Company was tracking tens of millions of dollars below the revenue trajectory provided to investors.

DEADLINE: April 29, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/nextdoor-holdings-inc-f-k-a-khosla-ventures-acquisition-co-ii-loss-submission-form/?id=75597&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of KIND during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 29, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 18:55
Voxtur Analytics Corp. ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced its financial results for the three months and year ended December 31,...

at 18:45
Pfizer Inc. and Genmab A/S today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with...

at 18:45
Genmab A/S and Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or...

at 18:18
OverActive Media Corp. ("OverActive" or the "Company") , a global esports, and entertainment company for today's generation of fans, released its fourth quarter and year-end results for the three-and-twelve-month period ended December 31, 2023....

at 18:05
Men? Inc. (US:MENEF) ("Men?" or the "Company"), an online 24 karat jewelry brand, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. All amounts expressed herein reflect Canadian dollars, unless...

at 17:55
Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The...



News published on and distributed by: